Ubrogepant

What it is

Ubrogepant is a synthetic small molecule that blocks the CGRP receptor. It is sold as 50 mg and 100 mg tablets for swallowing at the start of a migraine attack. Chemically it is unrelated to the triptans and to anti-inflammatory painkillers, and it belongs to the class usually called gepants.

What the research says

For the one thing it is approved for — stopping an individual migraine attack in adults — two large randomised placebo-controlled trials show a real but modest effect: roughly 7 extra people in 100 pain-free at two hours compared with placebo, and roughly 11 extra per 100 free of their most troublesome symptom. Head-to-head network comparisons put it below most triptans for both outcomes, though with fewer adverse events than some triptans and without their cardiovascular constraints. Side effects in the trials were mild and close to placebo; the more serious concerns — hypersensitivity, raised blood pressure and Raynaud's phenomenon — come from post-marketing reports with no rates attached.

Evidence grade: Well established.

How it works

Drug class: Calcitonin gene-related peptide (CGRP) receptor antagonist — an oral small-molecule "gepant"

Ubrogepant blocks the receptor for calcitonin gene-related peptide, a signalling molecule released around the trigeminal nerve and blood vessels of the head during a migraine attack. Unlike the older triptans it does not constrict blood vessels through serotonin receptors. It is a white to off-white powder, practically insoluble in water, taken as a tablet; it is broken down mainly by the liver enzyme CYP3A4 and leaves the body mostly in bile and faeces, with a half-life of about 5 to 7 hours. (Source 1)

What it is used for

• Two large placebo-controlled trials found about 7 to 9 extra people per 100 pain-free at two hours and about 10 to 11 extra per 100 free of their most bothersome symptom. Sustained pain freedom to 24 hours was not significant for 50 mg in one of the trials. Evidence: established. (Source 2)
• Explicitly excluded. The label carries a Limitations of Use statement that ubrogepant is not indicated for preventing migraine, and we found no trial of it as a preventive. Evidence: not-supported. (Source 3)
• Off-label against the label's stated indication, which is acute treatment of a migraine attack. A crossover trial in 477 adults found moderate or severe headache avoided after 46% of prodrome events treated with 100 mg against 29% with placebo. One trial, industry-funded, with adverse events 17% against 12%. Evidence: limited. (Source 4)
• Off-label: the indication is for adults. The only evidence we found is a 23-patient retrospective chart review that pooled ubrogepant with five other CGRP drugs, which cannot support any conclusion about ubrogepant in this age group. Evidence: unknown. (Source 5)
• Not a labelled indication. Network meta-analyses put ubrogepant below most triptans for pain freedom and pain relief at two hours, but record that some triptans carried more adverse events and that the gepants lack the cardiovascular risk that limits triptan use. No trial has tested it in a triptan-contraindicated population. Evidence: limited. (Source 6)

Interactions

• Grapefruit juice (label): Grapefruit juice is named on the label as a moderate CYP3A4 inhibitor, in the same list as cyclosporine and fluconazole. Blocking CYP3A4 slows the clearance of ubrogepant and raises its blood levels, so the label calls for a dose adjustment when the two are used together. (Source 7)
• St John's wort (label): St John's wort is named on the label among the strong CYP3A4 inducers. Inducing that enzyme clears ubrogepant faster, and the label states that in people taking strong inducers loss of ubrogepant effect is expected and the combination should be avoided. The measured size of the effect comes from rifampin, where exposure fell by 80%. (Source 8)
• Curcumin (the active constituent of turmeric extracts) (theoretical): Ubrogepant is carried out of cells by the BCRP and P-gp transporters. Curcumin is named on the label among the inhibitors of those transporters that may increase ubrogepant exposure, and a dose adjustment is called for. The label states no clinical interaction study with transporter inhibitors was done, and the predicted maximum rise in exposure is under twofold. (Source 8)
• Strong CYP3A4 inhibitors such as ketoconazole, itraconazole and clarithromycin (pharmacokinetic study): Ketoconazole raised ubrogepant exposure 9.7-fold and peak concentration 5.3-fold in a dedicated study. Strong CYP3A4 inhibitors are a contraindication, not just a caution. (Source 9)
• Rifampin and other strong CYP3A4 inducers (pharmacokinetic study): Rifampin cut ubrogepant exposure by 80% in a dedicated study, which is why loss of effect is expected with strong inducers. (Source 9)
• Verapamil and other moderate CYP3A4 inhibitors (pharmacokinetic study): Verapamil raised ubrogepant exposure about 3.5-fold and peak concentration about 2.8-fold, which is the basis for the dose adjustment required with moderate inhibitors, grapefruit juice among them. (Source 9)
• A high-fat meal (pharmacokinetic study): A high-fat meal delayed the peak blood level by two hours and lowered the peak by 22%, without changing total exposure. The trials did not control for food and the label states the tablet can be taken with or without it — though a two-hour delay matters for a drug taken to stop an attack in progress. (Source 10)
• Alcohol (label): We found no study of ubrogepant with alcohol. The label's list of co-administered agents formally evaluated for interaction covers oral contraceptives, paracetamol, naproxen, sumatriptan, esomeprazole and three CGRP antibodies or gepants — alcohol is not among them, and no alcohol interaction is described anywhere on the label. (Source 9)
• Sumatriptan and other acute migraine drugs taken in the same attack (pharmacokinetic study): No significant pharmacokinetic interaction was found when ubrogepant was given with sumatriptan, paracetamol or naproxen. This is a blood-level finding only; it says nothing about whether combining them works better or is safer. (Source 9)

Stopping it

• Ubrogepant is taken attack by attack rather than continuously, so there is no taper and we found no description of a withdrawal syndrome or of dependence in the literature we searched. The nearest thing to a stopping rule on the label is a limit on how often it is used: the label states that the safety of treating more than 8 migraines in a 30-day period has not been established. (Source 11)
• Long-term intermittent use was studied for up to a year in 813 patients who treated at least two attacks a month; 2.5% stopped the drug because of an adverse reaction, most often nausea. That is the only quantified discontinuation figure we found. (Source 12)
• The label gives three specific reasons to stop and not restart: a serious or severe hypersensitivity reaction, signs or symptoms of Raynaud's phenomenon, and blood pressure that is newly raised or inadequately controlled. In the reported Raynaud's cases, stopping usually resolved the symptoms. (Source 13)

What goes wrong

Nausea, sleepiness and dry mouth were the common adverse reactions, at rates only slightly above placebo and clearly dose-related. (Source 12)

• Randomized trial, High certainty.
• Size: 2,423 patients across the two placebo-controlled trials (placebo N=984, 50 mg N=954, 100 mg N=485); 3,624 subjects exposed overall.
• Who: Adults with migraine in the phase 3 programme.
• How long: single attack, with a separate 1-year open-label extension in 813 patients.
• Result: Nausea 2% placebo, 2% at 50 mg, 4% at 100 mg; somnolence (including sedation and fatigue) 1%, 2%, 3%; dry mouth 1%, <1%, 2%. At 50 mg only somnolence exceeded placebo, by 1 percentage point. In the 1-year extension, 2.5% of patients were withdrawn because of an adverse reaction, most often nausea.
• Funding: industry-funded; figures from the FDA label's presentation of the sponsor's trials.

Limit of this finding: Dry mouth is listed in a table headed "at a Frequency Greater than Placebo" yet the 50 mg column shows <1% against 1% for placebo, which contradicts the table's own inclusion rule. Read the table as the pooled picture, not as a per-dose comparison.

Table 2: Adverse Reactions Occurring in At Least 2% and at a Frequency Greater than Placebo in Studies 1 and 2 | Placebo (N= 984) % | UBRELVY 50 mg (N=954) % | UBRELVY 100 mg (N=485) % Nausea | 2 | 2 | 4 Somnolence* | 1 | 2 | 3 Dry Mouth | 1 | <1 | 2 *Somnolence includes the adverse reaction-related terms sedation and fatigue.

Total adverse events in the first trial were lower on 50 mg than on placebo and higher on 100 mg. (Source 2)

• Randomized trial, High certainty.
• Size: 1,672 participants.
• Who: Adults with migraine treating one attack.
• How long: 48 hours after the initial or optional second dose.
• Result: Adverse events 12.8% placebo, 9.4% at 50 mg, 16.3% at 100 mg. Serious adverse events within 30 days in the ubrogepant groups were appendicitis, spontaneous abortion, pericardial effusion and seizure, none within 48 hours of dosing.
• Funding: industry-funded (Allergan)

Limit of this finding: The rate at 50 mg is below placebo while the rate at 100 mg is above it, so the overall adverse-event count does not form a dose gradient and the 50 mg figure should not be read as the drug being better tolerated than placebo.

Adverse events within 48 hours after the initial or optional second dose were reported in 12.8% of participants in the placebo group, in 9.4% in the 50-mg ubrogepant group, and in 16.3% in the 100-mg ubrogepant group.

Treating during the prodrome produced more adverse events than placebo. (Source 4)

• Randomized trial, Moderate certainty.
• Size: 918 treated prodrome events in 480 participants.
• Who: US adults with migraine, crossover design.
• How long: 48 hours after each dose.
• Result: Adverse events within 48 hours after 77 (17%) of 456 events treated with ubrogepant 100 mg vs 55 (12%) of 462 treated with placebo — an absolute difference of about 5 percentage points, a number needed to harm of about 20 treated events.
• Funding: industry-funded (AbbVie)

Adverse events that occurred within 48 h after study-drug administration were reported after 77 (17%) of 456 qualifying prodrome events that had been treated with ubrogepant and after 55 (12%) of 462 events that had been treated with placebo.

Serious hypersensitivity reactions, including anaphylaxis, have been reported after approval and now contraindicate re-use. (Source 14)

• Official position, Certainty not rated.
• Size: not stated; spontaneous post-approval reports.
• Who: People taking ubrogepant outside trials.
• How long: reactions reported minutes, hours or days after a dose.
• Result: No rates are given. The label states most reactions occurred within hours and were not serious, that some led to discontinuation, and that a history of serious hypersensitivity to ubrogepant is a contraindication.
• Funding: not applicable (regulatory label; this DailyMed version retrieved in 2026)

Hypersensitivity reactions, including anaphylaxis, dyspnea, facial or throat edema, rash, urticaria, and pruritus, have been reported with use of UBRELVY. Hypersensitivity reactions can occur minutes, hours, or days after administration. Most reactions occurred within hours after dosing and were not serious, and some reactions led to discontinuation. If a serious or severe hypersensitivity reaction occurs, discontinue UBRELVY and institute appropriate therapy [see Contraindications (4) and Adverse Reactions (6.2)].

New or worsened high blood pressure has been reported with CGRP antagonists including ubrogepant, sometimes needing treatment or admission. (Source 15)

• Official position, Certainty not rated.
• Size: not stated; spontaneous post-approval reports.
• Who: People taking CGRP antagonists, some with pre-existing hypertension risk factors.
• How long: may occur at any time, most often within 7 days of starting.
• Result: No rates are given. The label records cases requiring drug treatment for hypertension and, in some cases, hospitalisation, and that the CGRP antagonist was discontinued in many reported cases.
• Funding: not applicable (regulatory label)

Limit of this finding: Post-marketing reports have no denominator, so this establishes that the events occur, not how often.

There were cases requiring initiation of pharmacological treatment for hypertension and, in some cases, hospitalization. Hypertension may occur at any time during treatment, but was most frequently reported within 7 days of therapy initiation.

Raynaud's phenomenon, sometimes with serious outcomes, has been reported with CGRP antagonists including ubrogepant. (Source 13)

• Official position, Certainty not rated.
• Size: not stated; spontaneous post-approval reports.
• Who: People taking small-molecule CGRP antagonists, including those with pre-existing Raynaud's.
• How long: symptom onset a median of 1.5 days after dosing.
• Result: No rates are given. The label states many reported cases had serious outcomes including hospitalisation and disability, generally from debilitating pain, and that symptoms usually resolved when the drug was stopped.
• Funding: not applicable (regulatory label)

In reported cases with small molecule CGRP antagonists, symptom onset occurred a median of 1.5 days following dosing. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain.

The label carries two absolute contraindications: concomitant strong CYP3A4 inhibitors, and a history of serious hypersensitivity to ubrogepant. (Source 16)

• Official position, Certainty not rated.
• Size: not stated.
• Who: People prescribed ubrogepant.
• How long: not applicable.
• Result: No rates are given. These are stated as contraindications rather than cautions; the hypersensitivity reactions behind the second one have included anaphylaxis, dyspnoea and facial or throat oedema.
• Funding: not applicable (regulatory label)

With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions (7.1)] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. Reactions have included anaphylaxis, dyspnea, and facial or throat edema [see Warnings and Precautions (5.1)]

What the evidence supports

Ubrogepant made more people pain-free at two hours than placebo in the first phase 3 trial. (Source 2)

• Randomized trial, High certainty.
• Size: 1,672 participants (559 placebo, 556 at 50 mg, 557 at 100 mg)
• Who: Adults with migraine with or without aura treating a single attack of moderate or severe pain.
• How long: single attack, outcomes at 2 and 24 hours.
• Result: Pain freedom at 2 hours 11.8% placebo, 19.2% at 50 mg (P=0.002) and 21.2% at 100 mg (P<0.001) — absolute differences of 7.4 and 9.4 percentage points, numbers needed to treat of about 14 and 11. Freedom from the most bothersome symptom 27.8% placebo, 38.6% at 50 mg (P=0.002) and 37.7% at 100 mg (P=0.002) — absolute differences 10.8 and 9.9 points, numbers needed to treat about 10.
• Funding: industry-funded (Allergan)

Limit of this finding: The 100 mg dose was no better than 50 mg for the most bothersome symptom (37.7% vs 38.6%), so the response does not rise with dose for that outcome. This passage is the trial's results section; the authors' own conclusion, not quoted here, adds that further trials are needed to determine the durability and safety of ubrogepant and to compare it with other migraine drugs.

The percentage of participants who had freedom from pain at 2 hours was 11.8% in the placebo group, 19.2% in the 50-mg ubrogepant group (P = 0.002, adjusted for multiplicity, for the comparison with placebo), and 21.2% in the 100-mg ubrogepant group (P<0.001). The percentage of participants who had freedom from the most bothersome symptom at 2 hours was 27.8% in the placebo group, 38.6% in the 50-mg ubrogepant group (P = 0.002), and 37.7% in the 100-mg ubrogepant group (P = 0.002).

A second phase 3 trial reproduced the effect at 50 mg with explicit absolute differences and confidence intervals. (Source 17)

• Randomized trial, High certainty.
• Size: 1,686 randomised; 1,465 treated; 1,355 evaluable for efficacy (mean age 41.5 years, 90% female)
• Who: Adults with 2 to 8 migraine attacks a month, treating one attack, at 99 US clinics.
• How long: single attack, outcome at 2 hours.
• Result: Pain freedom at 2 hours 21.8% (101/464) at 50 mg vs 14.3% (65/456) placebo — absolute difference 7.5% (95% CI 2.6% to 12.5%), P=.01, number needed to treat about 13. Most bothersome symptom free 38.9% (180/463) vs 27.4% (125/456) — absolute difference 11.5% (95% CI 5.4% to 17.5%), P=.01, number needed to treat about 9.
• Funding: industry-funded (Allergan)

Limit of this finding: The denominators shift within the trial report: efficacy percentages use the 1,355 participants evaluable for efficacy while adverse-event rates use the 1,465 in the safety population, and the two co-primary outcomes have denominators one participant apart (464 and 463 at 50 mg) with no explanation given.

Pain freedom at 2 hours was reported by 101 of 464 participants (21.8%) in the ubrogepant 50-mg group, 90 of 435 (20.7%) in the ubrogepant 25-mg group, and 65 of 456 (14.3%) in the placebo group (absolute difference for 50 mg vs placebo, 7.5%; 95% CI, 2.6%-12.5%; P = .01; 25 mg vs placebo, 6.4%; 95% CI, 1.5%-11.5%; P = .03).

Taking ubrogepant during the migraine prodrome, before the headache started, prevented moderate or severe headache more often than placebo. (Source 4)

• Randomized trial, Moderate certainty.
• Size: 518 randomised, 477 in the modified intention-to-treat population, 841 prodrome events treated.
• Who: US adults aged 18 to 75 with 2 to 8 monthly attacks, in a crossover design; 88% female.
• How long: 24 hours after each treated prodrome event.
• Result: Absence of moderate or severe headache within 24 hours after 190 (46%) of 418 prodrome events treated with ubrogepant 100 mg vs 121 (29%) of 423 treated with placebo; odds ratio 2.09 (95% CI 1.63 to 2.69), p<0.0001. Absolute difference about 17 percentage points.
• Funding: industry-funded (AbbVie)

Limit of this finding: One of the source's own percentages does not match its fraction: 190 of 418 is 45.5%, which rounds to 45%, but the paper prints 46%. The counts are the reliable part. The trial was funded by AbbVie, which makes the drug.

Absence of moderate or severe headache within 24 h after a dose occurred after 190 (46%) of 418 qualifying prodrome events that had been treated with ubrogepant and after 121 (29%) of 423 qualifying prodrome events that had been treated with placebo (odds ratio 2·09, 95% CI 1·63-2·69; p<0·0001).

What the evidence does not support

The 25 mg dose tested in the second trial failed on one of the two co-primary outcomes, and that dose was never marketed. (Source 17)

• Randomized trial, High certainty.
• Size: 435 to 456 evaluable participants per arm.
• Who: Adults with migraine treating a single attack.
• How long: single attack, outcome at 2 hours.
• Result: Most bothersome symptom freedom at 2 hours 34.1% (148/434) at 25 mg vs 27.4% (125/456) placebo — absolute difference 6.7% (95% CI 0.6% to 12.7%) with P=.07, which did not reach significance in the trial's testing scheme.
• Funding: industry-funded (Allergan)

Limit of this finding: The reported confidence interval (0.6% to 12.7%) excludes zero while the accompanying p value is .07, which cannot both be true on the same test; the trial used multiplicity-adjusted testing for the co-primary endpoints, so the p value governs. A reader should treat the 25 mg result for this outcome as not demonstrated.

25 mg vs placebo, 6.7%; 95% CI, 0.6%-12.7%; P = .07).

Sustained freedom from pain between 2 and 24 hours was not significant for the 50 mg dose in the first trial. (Source 18)

• Randomized trial, High certainty.
• Size: 418 to 457 participants per arm across the two trials.
• Who: Adults with migraine treating a single attack.
• How long: 2 to 24 hours after the dose.
• Result: Sustained pain freedom 2 to 24 hours: Study 1 12.7% at 50 mg vs 8.6% placebo, marked "NS" (not statistically significant), and 15.4% at 100 mg vs 8.6% (p=0.002); Study 2 14.4% at 50 mg vs 8.2% placebo (p=0.005).
• Funding: industry-funded; the table is the FDA label's presentation of the sponsor's trials.

Limit of this finding: The label's p value for pain freedom in Study 2 (0.007) differs from the published trial report for the same comparison (P=.01). The two sources are describing the same data with different analyses, so neither p value should be quoted as the definitive one. The N values in this table are the participants who actually treated a migraine, not the numbers randomised. The same label states Study 1 randomised 559 to placebo, 556 to 50 mg and 557 to 100 mg, and Study 2 randomised 563 to placebo and 562 to 50 mg, so 422 is not the size of the 50 mg arm.

Sustained Pain Freedom 2-24 hours | | N | 418 | 441 | 452 | 457 | 451 % Responders | 12.7 | 15.4 | 8.6 | 14.4 | 8.2 p value | *NS | 0.002 | | 0.005 | * Not statistically significant (NS)

In a network meta-analysis of 64 trials, most triptans outperformed ubrogepant for both pain freedom and pain relief at two hours. (Source 6)

• Meta-analysis, Moderate certainty.
• Size: 64 randomised trials, 46,442 participants (74% to 87% women, mean ages 36 to 43)
• Who: Adults treating acute migraine attacks.
• How long: 2 hours after the dose.
• Result: Odds ratios favouring most triptans over ubrogepant ranged from 1.54 (95% CI 1.00 to 2.37) to 3.05 (2.02 to 4.60) for pain freedom at 2 hours, and from 1.38 (1.02 to 1.88) to 3.13 (2.35 to 4.15) for pain relief at 2 hours. Ubrogepant, rimegepant and lasmiditan did not differ significantly from one another.
• Funding: not stated in the abstract; published in JAMA Network Open.

Limit of this finding: These are indirect comparisons across trials rather than head-to-head trials, and the lower bound of the pain-freedom range touches 1.00, so the weakest triptan-versus-ubrogepant comparisons are not clearly separated. This passage is the efficacy half of the review's results; the adverse-event comparison, in which lasmiditan carried the highest risk and several triptans a higher risk than the gepants, is quoted separately.

and ubrogepant (range: OR, 1.54 [95% CI, 1.00-2.37] to OR, 3.05 [95% CI, 2.02-4.60]).

An American College of Physicians network meta-analysis found triptan plus NSAID combinations more effective than gepants. (Source 19)

• Systematic review, Low certainty.
• Size: 21 head-to-head and 165 placebo-controlled trials.
• Who: Adults with acute attacks of episodic migraine.
• How long: pain outcomes at 2 hours and pain freedom up to 48 hours.
• Result: Triptan and NSAID combinations were more effective than gepants, rated low certainty of evidence; triptan regimens however often carried a higher risk of adverse events. One included study found triptans more cost-effective than ditans and gepants.
• Funding: American College of Physicians (PROSPERO CRD42023441146)

Limit of this finding: The gepant comparison is rated low certainty of evidence and the review notes that many comparisons lacked sufficient evidence to draw conclusions. The same review records that triptan regimens often had more adverse events, so effectiveness and tolerability point in opposite directions. The review's own limitations add that its harms assessment was confined to randomised trials.

Triptan and NSAID combinations were more effective for pain outcomes at 2 hours and pain freedom up to 48 hours compared with acetaminophen (low COE), gepants (low COE), NSAIDs (high COE), and triptan monotherapy (moderate COE).

Where the evidence is mixed

A retrospective chart review of CGRP therapies in adolescents and young adults reported high improvement rates and few side effects, but cannot separate ubrogepant from the other drugs used. (Source 5)

• Case series, Very low certainty.
• Size: 23 patients aged 12 to 21 at one paediatric headache centre over three years.
• Who: Adolescents and young adults with chronic migraine (78.3%), episodic migraine, new daily persistent headache or post-traumatic headache, unresponsive to standard treatment.
• How long: three-year retrospective period; benefits reported greatest beyond six months.
• Result: 91.3% had reduced migraine duration and intensity; 82.6% had fewer headache days at one month and 87% at three months, with nearly 40% achieving more than a 50% reduction; 95.7% reported no side effects; 69.6% chose to continue.
• Funding: not stated in the abstract.

Limit of this finding: 23 patients, no control group, no blinding, outcomes taken from chart notes and phone follow-up, and ubrogepant was given among five other CGRP drugs and sometimes with onabotulinumtoxinA, so nothing here can be attributed to ubrogepant. The 95.7% side-effect-free figure in particular cannot be compared with the placebo-controlled trials. The word 'significant' in this abstract is not a statistical claim: the study reports no p value, confidence interval or control group anywhere, so 'resulted in significant improvements' is the authors' description of chart notes. With 23 patients, one patient moves any of these percentages by 4.3 points, so the single decimal place is misleading.

The study included 23 patients, primarily treated for chronic migraine (CM) (78.3%), with a smaller subset addressing episodic migraine (EM), new daily persistent headaches (NDPHs), and post-traumatic headaches (PTHs). Comprehensive demographic and clinical data, including age, treatment duration, history of preventive treatment failures, and comorbidities like psychiatric conditions and sleep disorders, were collected. Anti-CGRP therapies, particularly when combined with traditional treatments or OnabotulinumtoxinA, resulted in significant improvements: 91.3% of patients experienced reduced migraine duration and intensity, 82.6% reported improvements in other bothersome symptoms, and 73.9% saw an improved response to rescue medications.

Where the research disagrees

How ubrogepant compares with triptans, and whether that comparison should drive the choice

• Yang and colleagues, 2021 network meta-analysis, Network meta-analysis of 64 randomised trials, 46,442 participants; indirect comparisons: lasmiditan, rimegepant, and ubrogepant were associated with higher ORs compared with placebo but lower ORs compared with most triptans. However, the lack of cardiovascular risks for these new classes of migraine-specific treatments may offer an alternative to triptans. (Source 20)
• Gartlehner and colleagues, 2025 review for the American College of Physicians, Systematic review and network meta-analysis of 21 head-to-head and 165 placebo-controlled trials, with certainty-of-evidence ratings: Triptan regimens, however, often had a higher risk for adverse events. One study found triptans more cost-effective than ditans and gepants. (Source 19)

Whether the 25 mg dose worked for the most bothersome symptom in the second phase 3 trial

• The trial's reported confidence interval, Co-primary endpoint in a randomised placebo-controlled trial, with multiplicity-adjusted testing; the interval excludes zero while the p value does not reach 0.05: 25 mg vs placebo, 6.7%; 95% CI, 0.6%-12.7%; P = .07). (Source 17)
• The trial's own conclusion, Same trial; the authors treat the 25 mg result for this endpoint as not demonstrated: absence of the most bothersome migraine-associated symptom at 2 hours only with the 50-mg dose. (Source 21)

How much

• Reference intake: Dosing is set by the prescriber. As a position, the label states the dose as 50 mg or 100 mg taken orally with or without food, with an optional second dose at least 2 hours after the first. (Source 11)
• Upper limit: The label's stated maximum is 200 mg in any 24-hour period, and it states that the safety of treating more than 8 migraines in a 30-day period has not been established. (Source 11)
• Studied: The first phase 3 trial randomised participants to placebo, 50 mg or 100 mg for a single attack, with an optional second dose. (Source 2)
• Studied: The second phase 3 trial used 50 mg and 25 mg against placebo; the 25 mg arm failed one co-primary endpoint. (Source 17)
• Studied: The prodrome trial used 100 mg given at the onset of a qualifying prodrome event. (Source 22)

A common belief, and what the research shows

The belief: Ubrogepant is a newer, better migraine drug than the triptans.

What the research shows: Newer, yes; more effective, no, on the evidence so far. A network meta-analysis of 64 trials and 46,442 participants found that lasmiditan, rimegepant, and ubrogepant were associated with higher ORs compared with placebo but lower ORs compared with most triptans. An ACP review reached the same ordering, reporting that Triptan and NSAID combinations were more effective for pain outcomes at 2 hours and pain freedom up to 48 hours compared with acetaminophen (low COE), gepants (low COE). What the gepants do offer is a different side-effect and cardiovascular profile, which is a reason to choose them in some people rather than a reason to prefer them generally.

Questions and answers

What is it?

Ubrogepant is a synthetic small molecule that blocks the receptor for calcitonin gene-related peptide, a nerve signalling protein involved in migraine. It is a white to off-white powder, practically insoluble in water, sold as 50 mg and 100 mg tablets. It is chemically unrelated to the triptans and to anti-inflammatory painkillers. (Source 1)

What does it do in the body?

It blocks CGRP receptors, interrupting one of the signalling pathways that drives migraine pain, without narrowing blood vessels the way triptans do. It is cleared mainly by the liver enzyme CYP3A4, which is why so many of its interactions involve drugs, foods and supplements that affect that enzyme. Peak levels are reached in about an hour and a half. (Source 9)

Is it good or bad for you?

Modestly good for the job it was tested on, and only that job. In two trials, pain freedom at two hours rose from about 12 to 14 per 100 on placebo to about 19 to 22 per 100 on ubrogepant — so roughly one extra person in every 13 or 14 became pain-free who would not have. It is not a preventive, and the label states so explicitly. Post-marketing reports add hypersensitivity, raised blood pressure and Raynaud's phenomenon without rates. (Source 3)

How do you get more of it?

Does not apply in the sense it would for a nutrient: ubrogepant is a prescription-only medicine with no dietary source and no bodily requirement. As a position, the label's stated dose is 50 mg or 100 mg orally with or without food, with an optional second dose at least two hours later and a stated 24-hour ceiling of 200 mg. (Source 11)

If it is harmful, what reduces it?

There is no antidote and no procedure for removing it; its half-life is about 5 to 7 hours and it leaves the body mostly in bile and faeces. Where harm appears, the label's answer is to stop the drug: discontinue for a serious hypersensitivity reaction, for Raynaud's symptoms, or where blood pressure cannot be controlled. Strong CYP3A4 inducers do lower its levels sharply, but that is an interaction to avoid rather than a remedy. (Source 15)

Why might someone be low in it or missing it?

Nobody is deficient in ubrogepant; it is not something the body makes or needs. The closest real phenomenon is having too little of it in the blood to work: the label states that in people taking strong CYP3A4 inducers such as phenytoin, barbiturates, rifampin or St John's wort, loss of effect is expected, and rifampin cut exposure by 80% in a dedicated study. (Source 8)

Which whole foods contain it or feed it?

No food contains ubrogepant. Food matters only for absorption and for interaction: a high-fat meal pushed the peak concentration two hours later and 22% lower without changing total exposure, and grapefruit juice is named on the label as a moderate CYP3A4 inhibitor that requires a dose adjustment because it raises ubrogepant levels. (Source 10)

What happens if you do not have it?

Not taking it has no consequence in itself; migraine attacks run their course or are treated another way. What the trials quantify is the difference it makes to one attack: without it, 11.8% to 14.3% of people were pain-free at two hours, against 19.2% to 21.8% with it. Most people treated gain nothing from any given dose, which is what a number needed to treat of about 13 means. (Source 17)

How can you test for it?

There is no blood test used to guide ubrogepant treatment, and no test for migraine itself; the trials enrolled people on clinical history, requiring at least a year of migraine with two to eight attacks a month. What does get measured is blood pressure, because new or worsening hypertension has been reported after approval. The outcome measured in the trials was the person's own report of pain and of their most bothersome symptom two hours after the dose. (Source 15)

References

1. DailyMed (U.S. National Library of Medicine). UBRELVY (ubrogepant) tablet — DESCRIPTION (Allergan, Inc.). 2025. Read the source
2. New England Journal of Medicine. Ubrogepant for the Treatment of Migraine. 2019. PMID 31800988, DOI 10.1056/NEJMoa1813049. Read the source
3. DailyMed (U.S. National Library of Medicine). UBRELVY (ubrogepant) tablet — INDICATIONS AND USAGE (Allergan, Inc.). 2025. Read the source
4. The Lancet. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. 2023. PMID 37979595, DOI 10.1016/S0140-6736(23)01683-5. Read the source
5. Brain Sciences. Effectiveness and Tolerability of Anti-Calcitonin Gene-Related Peptide Therapy for Migraine and Other Chronic Headaches in Adolescents and Young Adults: A Retrospective Study in the USA. 2024. PMID 39335375, DOI 10.3390/brainsci14090879. Read the source
6. JAMA Network Open. Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis. 2021. PMID 34633423, DOI 10.1001/jamanetworkopen.2021.28544. Read the source
7. DailyMed (U.S. National Library of Medicine). UBRELVY (ubrogepant) tablet — 7.1 CYP3A4 Inhibitors (Allergan, Inc.). 2025. Read the source
8. DailyMed (U.S. National Library of Medicine). UBRELVY (ubrogepant) tablet — 7.2 CYP3A4 Inducers and 7.3 BCRP and/or P-gp Only Inhibitors (Allergan, Inc.). 2025. Read the source
9. DailyMed (U.S. National Library of Medicine). UBRELVY (ubrogepant) tablet — 12.3 Pharmacokinetics, In Vivo Drug Interaction Studies (Allergan, Inc.). 2025. Read the source
10. DailyMed (U.S. National Library of Medicine). UBRELVY (ubrogepant) tablet — 12.3 Pharmacokinetics, Effect of Food (Allergan, Inc.). 2025. Read the source
11. DailyMed (U.S. National Library of Medicine). UBRELVY (ubrogepant) tablet — 2.1 Recommended Dosage (Allergan, Inc.). 2025. Read the source
12. DailyMed (U.S. National Library of Medicine). UBRELVY (ubrogepant) tablet — 6.1 Clinical Trials Experience (Allergan, Inc.). 2025. Read the source
13. DailyMed (U.S. National Library of Medicine). UBRELVY (ubrogepant) tablet — 5.3 Raynaud’s Phenomenon (Allergan, Inc.). 2025. Read the source
14. DailyMed (U.S. National Library of Medicine). UBRELVY (ubrogepant) tablet — 5.1 Hypersensitivity Reactions (Allergan, Inc.). 2025. Read the source
15. DailyMed (U.S. National Library of Medicine). UBRELVY (ubrogepant) tablet — 5.2 Hypertension (Allergan, Inc.). 2025. Read the source
16. DailyMed (U.S. National Library of Medicine). UBRELVY (ubrogepant) tablet — 4 CONTRAINDICATIONS (Allergan, Inc.). 2025. Read the source
17. JAMA. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial. 2019. PMID 31742631, DOI 10.1001/jama.2019.16711. Read the source
18. DailyMed (U.S. National Library of Medicine). UBRELVY (ubrogepant) tablet — 14 CLINICAL STUDIES (Allergan, Inc.). 2025. Read the source
19. Annals of Internal Medicine. Pharmacologic Treatment of Acute Attacks of Episodic Migraine: A Systematic Review and Network Meta-analysis for the American College of Physicians. 2025. PMID 40096693, DOI 10.7326/ANNALS-24-02034. Read the source
20. JAMA Network Open. Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis. 2021. PMID 34633423, DOI 10.1001/jamanetworkopen.2021.28544. Read the source
21. JAMA. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial. 2019. PMID 31742631, DOI 10.1001/jama.2019.16711. Read the source
22. The Lancet. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA — Methods. 2023. PMID 37979595, DOI 10.1016/S0140-6736(23)01683-5. Read the source